AI Analysis
AI-generated analysis. Always verify with the original filing.
Psyence Biomedical Ltd. entered into a settlement agreement with KAOS Capital Ltd. and Adam Arviv to resolve shareholder litigation. The Company will pay US$1,500,000 and facilitate the sale of KAOS Group's 50,220 common shares to a third party at US$5.00 per share, while KAOS agrees to a three-year standstill and full retraction of allegations.
Key Takeaways
1The Company will pay a settlement amount of US$1,500,000 to the KAOS Group.
2KAOS Group agreed to sell all 50,220 Subject Securities to a Company-designated purchaser at US$5.00 per share on February 13, 2026.
3KAOS Group is released from the C$75,000 Costs Award previously ordered by the Ontario Superior Court.
4The agreement includes a standstill provision prohibiting KAOS Group from acquiring securities or influencing the Company until February 9, 2029.
5KAOS Group agreed to a full retraction of the allegations made against the Company and its management.
6The Company denied all allegations and the settlement does not constitute an admission of liability.